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Agenda Advocates Global Equality in Medical Research
Trials and Drug Administration
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ABSTRACT: The New Women’s Health Agenda seeks to close the
discriminatory gap between men’s and women’s medical treatment
around the world. Often, women’s reproductive issues are the focus
of medical studies in which women are involved; however, chronic
diseases are quickly becoming a high health risk for the female population around the world. This comment explores the past, present,
and future of women’s global health. Throughout history, women
have been prevented from participating in clinical trials for reproductive protection reasons. The problem arises after men have successfully responded to treatment because the medication is then administered to both men and women. Women are still facing numerous
challenges in regards to proper healthcare today. Women today are
experiencing an increase in mental health diseases and chronic diseases such as heart disease, autoimmune diseases, and HIV/AIDS.
Women of color and of low socioeconomic status also face their own
unique challenges. This comment argues importance of a global
healthcare system in which men and women are treated as biologically different, but socially and psychologically equal.
AUTHOR: Margery R. Beltran is a second-year student at the University of Baltimore School of Law. She received her B.S. in Family
Science from Towson University in 2014 and was recently named the
Volume 5 Comments Editor for the University of Baltimore’s Journal
of International Law.
ACKNOWLEDGEMENTS: A very special thanks to Professor Natalie
Ram for her brilliant feedback, support, and flexibility while writing
this article and to Professor Dionne Koller for her remarkable patience and encouragement while teaching the legal research process
to her students.

97

2015-2016

UB Journal of International Law

TABLE OF CONTENTS
I. Introduction ................................................................................... 99
II. Historical Discrimination: A Timeline of Women’s Treatment . 100
Gender Bias and Discrimination ........................................... 100
a. A U.S. Historical Exploration of Women’s Medical
Research and Treatment.................................................. 103
i. Guinea Pigs: Early 19th Century Clinical Trials .......... 103
ii. Trial and Error: Policy Shifts in the U.S. Since the
Mid-1900s.................................................................. 103
iii. The 1990s and the Society for Women’s Health
Research .................................................................... 106
III. Testing Positive for Unequal Treatment Towards Women in
Modern Medicine .................................................................. 107
a. Biopsychosocial Differences: What really needs to be
addressed? ....................................................................... 107
i. Attitudes and Behaviors in the Healthcare Facility ..... 107
ii. Women of Color in Medicine ..................................... 108
iii. The Flaws of Structuralism Research ........................ 109
iv. International Human Health Rights: HIV/AIDS
Pandemic and Women ............................................... 112
b. Clinical Trials ................................................................. 114
i. Varied Biological Responses ....................................... 114
ii. Mental Health and Substance Abuse Trials ................ 114
iii. Menopause and Hormone Therapy ........................... 116
c. Criticisms of Women’s Health Initiatives and the
Neglect of Men ............................................................... 118
IV. The Future for Women Around the World................................ 119
a. Women and Health Initiative and a Global Perspective ... 119
b. The Future for Gender and Medicine ............................... 121
V. Conclusion ................................................................................. 123

98

Not Really a Battle of the Sexes

Vol. IV, No. II

I. Introduction
Between lifestyle changes and the shift to a longer-living population, women’s health, both reproductive and non-reproductive, has
become an issue on the rise throughout the field of public health.1
“The world still focuses very much maternal health and, more recently, family planning, which definitely reflect critical needs; [however],
the predominant view today is of women as reproductive beings,
which leads to neglect of women’s health in other stages of life,” explained Ana Langer, Professor at the Harvard T.H. Chan School of
Public Health.2 The New Women’s Health Agenda (“Agenda”) aims
to address what Langer calls the “double burden of disease among
women” in order to promote health to women of all ages around the
world.3
The Agenda’s double burden of disease integrates two scopes
of study in women’s health.4 The first burden and most commonly
studied are the problems that still exist in the realm of reproductive
health, infectious diseases, gender-based violence, and malnutrition.5
The second, and more recently emerging, is the epidemic of chronic
diseases.6 There is a drastic inequality in government focus on women’s reproductive and non-reproductive health around the world.7
The Agenda is concerned about the rise of chronic diseases and
the lack of preparedness, especially in low to middle socioeconomic
status countries.8 Langer also notes that chronic diseases and reproductive health problems are more common in the low to middle socioeconomic class countries, primarily in Europe and Africa.9

1.

2.
3.
4.
5.
6.
7.
8.

9.

Fiona Fleck, The New Women’s Health Agenda, 91 BULL. WORLD HEALTH ORG. 628
(2013). Ana Langer is an advocate for women’s health on the global level and has
served on the boards for multiple global health organizations over the past 25 years.
She is at the forefront of the Women and Health Initiative at the Harvard School of
Public Health.
Fleck, supra note 1.
Id.
Id.
Id.
Id.
Id.
Fleck, supra note 1 (“It seems that donors are not prepared to invest in the prevention,
detection and treatment of chronic diseases affecting women unless more progress is
made in the unfinished agenda of reproductive health.”).
See generally id.
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This comment explores the discrimination towards women in
medical research and treatment throughout the world while developing a clearer understanding of the Agenda’s objectives. Through a
combination of modern medical research analysis and a historical examination of gender discrimination in medical testing, this comment
argues that the Agenda is a necessity in the field of global health.
The Agenda, which was created in 2010 at the Harvard School of
Public Health, is quickly gaining recognition among global medical
researchers and academics.10 The Agenda aims to improve the outlook of women’s health research and treatment in order to bring
equality to women in their treatment for chronic diseases and reproductive health.11
II. Historical Discrimination: A Timeline of Women’s Treatment
Gender Bias and Discrimination
In the field of medicine, women fall victim to sex discrimination. However, traditional treatment of women has not been without its own rationale.13 According to Langer, there are valid concerns
in regard to including women in clinical trials, but that these concerns
should not bar women from participating in the trials:
There is evidence that discrepancies exist between men and
women in terms of the attention they receive for the problems they
have in common…Women are not recruited to trials for the testing of
drugs for chronic diseases that, once approved, are used by women.
Women are often not considered “stable enough” to participate in
such trials because of their menstrual cycles, because they may become pregnant during the trial and because they may be breastfeeding, which could incur risks for the baby. Therefore, women are excluded from many trials and as a result don’t get proper treatment
later.14
12

10.
11.
12.
13.

Id. at 629.
Id.
Anita Holdcroft, Gender Bias in Research: How Does it Affect Evidence Based Medicine?, 100 J. ROYAL SOC’Y OF MED. 2 (2007).
Fleck, supra note 1.
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Clinical research demonstrates gender bias in a number of
ways.15 A key issue in women’s discrimination is the field’s tendency to apply the research collected from male-dominated clinical trials
to women’s clinical treatment.16 While the rationale to protect the reproductive anatomy of women when collecting research is understandable, that rationale is counterintuitive on the macro-level goal of
improving the overall health of women.17 There is a huge discrepancy between clinical trials and treatment.18 Women must forego testing of a drug, but if it proves successful for men, it is then prescribed
to women.19
Anita Holdcroft provides the example of gender differences in
the treatment of coronary artery disease between men and women in
which male studies on heart disease are provided far more funding
than women.20 Holdcroft found coronary artery disease research
funding is far more generous to studies for males; however, the risk
of the disease is far higher for women.21 Women have a much higher
chance of dying from coronary artery disease than men.22 Therefore,
there should be more studies focused on either just women or the differences between men and women’s symptoms and reactions to medication treating coronary artery disease.23
The same result occurs across the medical field. For instance,
research strongly suggests women have stronger immune systems
than men,24 thus women have a naturally higher prevention of disease.25 Unfortunately, this also leaves women far more likely to de14.

15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.

Id. at 629; see also Holdcroft, supra note 12 (“The evidence bases of medicine may be
fundamentally flawed because there is an ongoing failure of research tools to include
sex differences in study design and analysis. The supporting bias which this methodology maintains creates a situation where guidelines based on the study of one sex may
be generalized and applied to both.”).
Holdcroft, supra note 12.
Fleck, supra note 1.
Holdcroft, supra note 12.
Id.
Id.
Id.
Id.
Id.
See generally Holdcraft, supra note 12.
Donna E. Shalala, Women Get Heart Disease Too: A Brief History of Gender Discrimination in Medical Research, 10 COLUM. J. GENDER & L. 57, 59 (2000).
Id.
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velop autoimmune diseases such as multiple sclerosis, lupus, scleroderma, and rheumatoid arthritis—all of which are unrelated to reproductive health issues.26 The Agenda can help broaden the narrow focus of the traditional reproductive health narrative to include chronic
diseases.27
In the past two decades, the U.S. National Institute of Health
(hereinafter “NIH”) has begun to acknowledge this lack of attention
to women’s specific health problems.28 In 1994, NIH implemented a
set of guidelines to ensure trial drugs would be tested on a wider
range of patients who would ultimately use the medication or therapy.29 Before the implementation of this policy, women were often
excluded from early stage drug trials as a precautionary measure.30
NIH decided that this was a substantial issue because there was little
information regarding how the drugs would affect women—the same
battle being fought by the Agenda.31
By 1997, 94% of NIH research grant proposals included women as subjects.32 But, almost twenty years since 1997, there is still a
discrepancy in research enrollment of men and women. To better
understand the continued discriminatory research practices, it is imperative to examine the historical context of gender differences in
medical research. Since the global initiative grew out of primarily
U.S. policy, an examination of U.S. policy changes will be conducted
henceforth to understand how the Agenda has shaped the international landscape regarding medical research for women.

26.
27.
28.
29.
30.

31.
32.

Id.
Fleck, supra note 1.
Shalala, supra note 24.
Id.
Id. Holdcroft noted in 2005, eight out of ten prescription drugs were withdrawn from
the U.S. prescription pharmaceuticals market due to their negative effects on women’s
health. Not only is administering drugs not tested on women a dangerous gamble to
women’s health, but it is also an extremely wasteful use of resources. Holdcroft, supra note 12.
Holdcroft, supra note 12.
Id.
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a. A U.S. Historical Exploration of Women’s Medical
Research and Treatment
i. Guinea Pigs: Early 19th Century Clinical Trials
In the early 19th century, African-American slave women were
the primary test subjects in clinical trials.33 These tests were conducted at a time when anesthesia was non-existent.34 Physicians at
this time would repeat the heinous and inhumane experiments on these women in order to find the best forms of treatment.35 Moving to
the 1900s, researchers around the world shifted to using institutionalized populations, including mental health patients, prisoners, and
concentration camp victims.36
By 1949, the abuses to the institutionalized had been revealed
to the global public and there was a movement formed to protect humans from unjust experimentation. This eventually culminated in the
Nuremburg Code.37 The code “set out ethical and legal standards for
the conduct of human research aimed at protecting human research
subjects from the types of experimentation practices used by the Nazis in World War II.”38 According to Rothenberg, the U.S. was still
slow to develop their clinical trial regulations after the code was implemented.39
ii. Trial and Error: Policy Shifts in the U.S. Since the Mid-1900s
As previously stated, there has been logical rationale behind
avoiding women’s inclusion in new drug trial treatment.40 Researchers do not want to be liable for potentially harming a woman’s fertility or an unborn child.41 At the most primal level, the human race,
like all other animals, wants to preserve its species.42 The Agenda
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.

Karen H. Rothenberg, Gender Matters: Implications for Clinical Research and Women’s Health Care, 32 HOUS. L. REV. 1201, 1220 (1996).
Id.
Id.
Id.
Id.
Id.
Rothenberg, supra note 33. Rothenburg believes that the U.S. changes in policy are
primarily attributed to the Thalidomide tragedy in the 1960s. Id.
See supra Section 1.
Fleck, supra note 1.
See generally id.
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does not criticize the protection and preservation of reproductive
health of women; it works to find ways to preserve and protect female reproduction health issues, while also ensuring proper treatment
for women with non-reproductive health problems.43
There was a great deal of hesitance in the field of medicine to
treat women with experimental drugs.44 Though NIH’s initiative was
not implemented until 1994, there was a small increase in the late
1980s in including women in clinical trials.45 Sarah Keitt attributes
the hesitance to include women to two distinct reasons: the first, being a general neglect to women throughout history; the second, being
the Thalidomide tragedy in the 1960s,46 which caused medical researchers to be more aware of their effects on unborn children.47 The
Thalidomide tragedy sparked stricter legislative regulation for women as test subjects in the 1960s and 1970s.48 Keitt believes that did far
more harm than good.49
Prior to this 1980’s shift of female inclusion, researchers fell
into one of two categories with regard to women in clinical trials; this
categorization is also attributed to women’s involvement in testing at
the time.50 Some researchers assumed women to simply be smaller
versions of men and thus viewed women as unnecessary test sub-

43.
44.
45.
46.

47.
48.
49.
50.

See generally id.
See generally Sarah K. Keitt, Sex & Gender: The Politics, Policy, and Practice of
Medical Research, 3 YALE J. HEALTH POL’Y L. & ETHICS 253 (2003).
Id.
“In 1962, the Kefauver-Harris Amendment, perhaps the most important piece of legislation regulating the conduct of clinical trials, was passed with the purpose of protecting children, pregnant women, and fetuses. The Kefauver-Harris amendment required
drug manufacturers to demonstrate that new drugs were safe and effective via adequate
and well-controlled clinical trials. This legislation was passed in response to the thousands of babies with severely deformed limbs as a result of utero exposure to Thalidomide (used to prevent morning sickness). Later, during the early 1970s, research revealed the daughters of women who took diethylstilbestrol during pregnancy had an
increased risk of vaginal cancer. In 1977, the [FDA] responded to these events by issuing guidelines that required women of childbearing potential to be excluded from
[drug trials until data from animal studies regarding development disturbances in embryonic or fetal was collected]. The only exception to these guidelines was for drugs
used in treatment of life-threatening or serious diseases.” Id. at 255.
Id. at 253.
Id.
Keitt, supra note 44.
Id. at 254.
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jects.51 The other group viewed women’s biology as too complicated
to study due to their hormonal cycles.52 The assumption of hormone
complications draws a question of irony in that researchers were preventing women from inclusion in medical trials for medication created to treat women.53 Critics have since pointed out that drugs tested
on men only, were also being prescribed to women even though the
researchers conducting the trials fully recognized that fluctuations of
hormones affect how a woman reacts to certain kinds of drugs.54 The
risks of some of those prescriptions administered could have been
very dangerous, and medical researchers at the time had very little
data on what sort of reactions women could have.55
By 1983, the then-Assistant for Secretary of Health, Dr. Edward Brandt noticed a distressing pattern in medical research.56
Brandt found that there was a plethora of information regarding menopause, pregnancy, and menstruation, but hardly any information on
chronic illnesses that affect both men and women, namely heart disease.57 To remedy this problem, Brandt formed a national task force
dedicated to analyzing women’s health issues.58
In 1985, the task force concluded that the lack of research on
women’s non-reproductive health issues was negatively affecting the
overall healthcare of women.59 The task force’s findings prompted
the official NIH guidelines for inclusion of women, particularly
women of childbearing potential, in federally funded clinical research.60 Despite the NIH’s efforts for female inclusion, advocates
for women’s health and the task force found that since the inclusion
guidelines were not “enforced,” trials were still being conducted in
the same way they were prior to the implementation of the guidelines.61

51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.

Id.
Id.
Shalala, supra note 24.
Id.
See generally Shalala, supra note 24.
Keitt, supra note 44.
Id. at 255-56.
Id. at 256.
Keitt, supra note 44, at 256.
Id.
Id. (“Women were still routinely excluded from clinical trials.”).
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iii. The 1990s and the Society for Women’s Health Research
In 1990, the increasingly frustrated and concerned advocates
for women’s health formed the Society for Women’s Health Research (hereinafter “Society”).62 The Society sought to enforce the
NIH clinical trial rules by placing pressure on the U.S. Congress to
involve the General Accounting Office.63
After a great deal of investigation, the General Accounting Office found that the “NIH policy had not been well communicated or
understood within NIH or the research community, was applied inconsistently across institutes, and only applied optional research.
NIH had also done little to encourage the analysis of studying sex differences in data.”64 The report found that only 13% of the NIH budget was allocated to women’s health research.65 The findings sparked
a serious shift in women’s health.66 Following the findings, researchers were informed by the government that they would be held accountable if they did not follow the NIH guidelines and that policies
had to be treated like mandates.67
As the 1990s progressed, various new proposals and bills began to develop to protect women’s treatment.68 By 1995, the FDA
had also proposed regulation requirements to include safety and efficacy data by gender.69 All the changes in the 1990’s provided more
accessible opportunities for women.70 By the 2000s, women were
proportionally represented in clinical trials with the exception of
pregnant women.71
Fortunately, abusive medical treatment is no longer an acceptable practice to any person, regardless of biological sex. There
are still many discrepancies between the way men and women are
treated in clinical trials. The Agenda seeks equality in the quality of
62.
63.
64.
65.

66.
67.
68.
69.
70.
71.

Id.
Id.
Id.
Caroline W. Jacobus, Legislative Responses to Discrimination in Women’s Health
Care: A Report Prepared for the Commission to Study Sex Discrimination in the Statutes, 16 WOMEN’S RTS. L. REP. 153, 174 (1995).
Keitt, supra note 44, at 257.
Keitt, supra note 44, at 257.
See generally Shalala, supra note 24.
See generally Shalala, supra note 24.
Keitt, supra note 44, at 258.
Id.
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treatment towards women in medical trials because modern medicine
is still discriminatory towards women.
III. Testing Positive for Unequal Treatment Towards Women in
Modern Medicine
a. Biopsychosocial Differences: What really needs to be
addressed?
i. Attitudes and Behaviors in the Healthcare Facility
Women tend to receive more direct health care over their life
span.72 This is primarily attributed to their reproductive health needs
and their longer life expectancy.73 In one study comparing the general treatment of men versus women in healthcare facilities, researchers concluded, “women’s health care tends to be comprised of drug
prescriptions and routine checks whereas major diagnostic and therapeutic interventions are more frequently performed on men.”74
In the past twenty to thirty years, physicians have changed their
notion about how women experience symptoms of illnesses and diseases.75 It was often assumed, throughout the field, that men and
women experience symptoms the same way.76 This could contribute
to the assumption that women could be prescribed the same treatments as men.77
According to Jacobus, in 1995, men were 6.5 times more likely
to be tested for common chronic diseases.78 “Women’s ailments are
more likely to be attributed to emotional rather than physical causes.”79 According to recent social demographic research conducted by
University of Michigan, both men and women develop the same
types of illnesses.80 The key differences arise in the frequency of

72.
73.
74.
75.
76.
77.
78.
79.
80.

Jacobus, supra note 65, at 174.
Id.
Jacobus, supra note 65, at 174.
Id.
Id.
Id.
Id.
Id.
Megan Veith, Note, The Continuing Gender-Health Divide: A Discussion of Free
Choice, Gender Discrimination, and Gender Theory as Applied to the Affordable Care
Act, 21 GEO. J. POVERTY L. & POL’Y 341, 345 (2014).

107

2015-2016

UB Journal of International Law

those illnesses and the “pace of death” among the sexes.81 Thus, both
should be treated according to their biological needs.82 Genderspecific medicine positively impacts both men and women:
Although [the modern] field of medicine originated from feminist critiques of the current health care system’s treatment of women
in the past, gender-specific medicine strives to help both women and
men, especially concerning gender difference in disease susceptibility
and lifespan. Gender-specific medicine is important because it seeks
to recognize the differences between men and women’s health, while
also ensuring that both genders are equally represented in medicine.83
The issue at hand is not to advocate for a healthcare system in
which women take precedence over men in clinical trials and treatment. The goal should be achieving just and fair treatment of both
men and women in medical research to ensure a healthier future for
all persons. Historically, research on women’s health is far less developed than that of men and thus, there may need to be an increased
focus on women’s health issues in the near future.84
ii. Women of Color in Medicine
A subcategory of disparities among women’s health is the treatment of women of color in
the healthcare system, especially with regard to clinical trials.
The health concerns of women of color, who compromise a crucial
percentage of the world’s population, are in need of attention from
researchers.85
Although various programs and policies throughout the world
have begun to mandate the inclusion of women in clinical trials,
many of the advancements fail to provide benefits to women of col-

81.
82.
83.

84.
85.

Veith, supra note 80.
Id.
Id. at 344. In regards to the modern involvement of the U.S. in women’s health
movements, “The gender-specific medicine movement has greatly benefitted women,
who have been the focus of much of the new scientific studies and research of the last
few decades. Thus, it may come to a surprise that the [Affordable Care Act] includes
more female-specific benefits that male-specific benefits.” Id. at 355.
See generally Keitt, supra note 44.
See generally Lisa C. Ikemoto, Deconstructing the Image Repertoire of Women of
Color: In the Shadow of Race: Women of Color in Health Disparities Policy, 39 U.C.
DAVIS L. REV. 1023 (2006).
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or.86 “[T]he core failure – inattention to the intersections of categories used for social ordering – leaves the particular ways that racialized patriarchy allocates health risks to women of color out of sight
and out of mind.”87 Lisa Ikemoto argues that in the past fifty years,
racism and patriarchy have been successfully addressed;88 however,
racism and patriarchy issues continue to act as completely separate
entities from initiatives to promote the health needs of women of color.89
As social health disparities continue to be acknowledged, social
scientists are gathering data on how biopsychosocial factors affect a
person’s health treatment.90 Researchers found that biological race,
socioeconomic status, and general lifestyle habits are the key factors
fueling all health disparities and differences in mortality rates among
races.91
According to Ikemoto, hardly any research has been conducted
on the specific disparities and needs for women of color92 because
they were assumed to be a subcategory of the already studied race
disparities and thus need no extra examination.93 Ikemoto raises her
concern that researchers are only addressing the problem in a fashion
that is far too narrow because they are only looking at the factor of
race, while disregarding gender.94 Ikemoto fears that “the narrowing
scope of the health disparities inquiry threatens to constrain the understanding of health, as well as to push the health needs of women
of color and others back into the shadows.”95 The world is quickly
recognizing health disparities among racial groups.
iii. The Flaws of Structuralism Research
In regards to the research collected and analyzed about race,
Ikemoto also criticizes the primary research and implications of the

86.
87.
88.
89.
90.
91.
92.
93.
94.
95.

Ikemoto, supra note 85, at 1025.
Id.
Id. at 1026.
Id.
Id.
Id.
Ikemoto, supra note 85, at 1026.
Id.
Id.
Id.
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structuralist school of thought.96 In other words, the research is collected under a framework that focuses on organizational structures in
society, and in this case, how those structures affect health outcomes
among racial classes.97
Structuralism analyzes how large societal influences, such as
governments or global policy organizations, affect the treatment of
humans.98 Leadership organization’s treatment towards groups of
people, regardless of whether they are subtle or not, can have a great
deal of effect on stereotypes and the way people react to one another.99 According to Ikemoto, structuralism can be one of the most successful ways to analyze governing organizations and their effects on
populations, but it should not be the only approach used.100 This theory can provide insight as to what sort of policy changes or legal interventions should be implemented.101
Structuralism is often the theory of choice because it assumes
racism is perpetuated through the operation of greater institutions.102
Under the structuralist theory, implementing strict programs and
providing cross-cultural training would eventually lead to the elimination of racism in healthcare.103 Application of this theory in program development can identify the changes in tangible practices,
which has the possibility of greatly improving the treatment of the
disparaged.104 The problem arises when the changes in practice do
not adapt with the fluid changes in ideology.105 According to Ikemoto, it is not the best nor is it the only theory in addressing disparities
to different races and women,106 because “racism and patriarchy persist even as their forms change. As new practices and standards

96.
97.
98.
99.
100.
101.

102.
103.
104.
105.
106.

Id.
Id.
See generally Ikemoto, supra note 85, at 1027.
See generally id.
Ikemoto, supra note 85, at 1027-28.
Id. (“While structuralist analysis is good at identifying opportunities for legal intervention. An exclusive focus on health care organizations and practices fails to fully account for how orders or power formed by racialized patriarchy can persist despite the
dismantling of specific institutional structures and practices.”).
Id. at 1048-49.
Id. at 1049.
Id. at 1050.
Id.
Ikemoto, supra note 85, at 1050.
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emerge, ideology flows in and provides context.”107 As the fluidity
and adaptation of racial and patriarchal issues develop, the structuralism theory is able to narrow down what the new challenges are to society and how they were shaped.108
Instead, Ikemoto recommends critically analyzing cultural
formation; while structuralism theory should continue to be used,
Ikemoto believes that implementing the added critical analysis will
greatly improve the health disparities of women of color.109 Critical
analysis of cultural formulation will give insight to not only the governing structure, but also to the governed.110 Ikemoto notes:
“[C]ritical cultural inquiry is sensitive to multi-axis difference, differential subordination, and the fact that ideology, including racialized patriarchy, adapts quickly to structural changes.”111
Structuralism theory is used by researchers to reveal issues in
difference of treatment among the sexes; however, the theory rarely
provides any inkling of recommendation as to how to correct the issues it discovers.112 For example, if health disparities are attributed to
race and gender separately and not under a holistic approach, women
of color fall into one of two categories of this assumption: that they
react to treatment the same way as the men in their particular race or
that they will react to treatment a certain way based on research primarily conducted on white women.113
Women of color are victimized on two levels. The first is the
standard biological discrimination, as addressed by the Agenda.114
The second is their psychosocial demographic factors including their
race and socioeconomic status.115 Women of color have health needs
that desperately need to be addressed and it is imperative that they do
not become a mere subcategory in race and gender studies.116
107.
108.
109.
110.
111.

112.
113.
114.
115.
116.

Id.
Id.
Id. at 1026.
Id.
Ikemoto, supra note 85, at 1026 (Ikemoto also discusses how this theory’s study of
ideology allows for “a more nuanced and complicated understanding of how inequality
becomes embedded in out understanding of [health].”).
Id. at 1050.
Id.
See generally id.
See generally id.
See generally id.
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iv. International Human Health Rights: HIV/AIDS Pandemic and
Women
Another relatively new health concern is the rise of HIV/AIDS
throughout the world. “To curb the spread of the pandemic, [we]
must focus on the structural and contextual determinants shaping the
course of the pandemic, especially the social or traditional practices
that violate women’s human rights and leave them more vulnerable to
HIV/AIDS.”117 The HIV/AIDS pandemic is posing challenges to the
international human rights of women throughout the world, primarily
in developing countries.118 Spectar argues that HIV/AIDS has become a global threat to the international human health rights for
women and should be sparking the attention of national leaders
around the world.119
There are numerous factors affecting the spread of HIV/AIDS
among women, particularly in developing countries.120 In general,
women are deemed to be powerless and of a lower status in developing countries.121 Under this generalization, women are much more
vulnerable to become victims of sexual abuse and coercion.122
Hence, women are far more likely to be pressured into a situation that
presents an exposure to possible infection of HIV or other sexually
transmitted diseases.123
Other prominent factors continuing the pandemic include “barbaric cultural practices” and domestic violence.124 Genital mutilation
continues to occur in many areas around the world.125 During the
mutilation process, women run the risk of contracting HIV and possibly bleeding to death from subsequent injuries.126 Moreover, many

117. J.M. Spectar, The Hydra Hath but One Head: The Socio-Cultural Dimensions of the
AIDs Epidemic & Women’s Right to Health, 21 B.C. THIRD WORLD L.J. 1, 2 (2001).
118. Id. at 3.
119. Id. (“In fact, the situation in developing countries is becoming increasingly grave—to
a degree that AIDS is effectively an “aggressor” or a global threat to women’s international human rights, particularly the right to health.”).
120. Id. at 4.
121. Spectar, supra note 117.
122. Id.
123. Id.
124. Id. at 6.
125. See generally id.
126. Spectar, supra note 117, at 6.
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countries still view violence towards a woman as a man’s right.127
Domestic violence “is a major socio-cultural condition that violated
women’s human right to health.”128 In domestic violence situations,
women are often in a position in which they cannot refuse sex and
usually do not have the option of using any sort of sexual protection.129 These factors raise serious issues in the treatment of women.
Women are not only thought to be second class citizens; they are also
more likely to be exposed to abusive situations in which they have no
control over what happens to their bodies.130
Many women in developing countries are afraid of the repercussions should they report any sort of abuse.131 According to Spectar, the legal systems of developing countries often side with abusers
and further traumatize the victims.132 In fact, in many developing
countries, both governing bodies and even family members discriminate against women with HIV/AIDS.133 There, women are often denied jobs, housing, and healthcare.134
To achieve the goals of the Agenda worldwide, the treatment
and view of women’s status throughout the world must be shifted.
Women in developing countries are stigmatized as lesser beings.135
The biopsychosocial stereotypes of women are the underlying issue
in the lack of just treatment to women in healthcare.
This is not to say men’s medical treatment should be neglected
or ignored, but merely that both research of men and women, of all
races and ages, should be on a level playing field. The goal of the
women’s health initiatives should be to increase recognition of women’s health, without causing a complete neglect of men’s health re127. Id. at 7 (It is important to note that domestic violence runs rampant through both developed and developing countries in different ways.).
128. Id.
129. Id.
130. See generally id.
131. Spectar, supra note 117, at 7.
132. Id. (“For example. In Tanzania, female rape victims who bring charges against their
attackers are discriminated against to the extent that these women (but not their male
attackers) are required to disclose their HIV-status.”).
133. Id.
134. Women with HIV/AIDS tend to be more stigmatized if they are monogamous wives.
Their in-laws often blame these women for exposing their son and his fate. Sometimes widows of men who died of AIDS are thrown out of their home and lose their
children to their in-laws. Id.
135. See generally id.
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search. The mindset must shift to recognize that men and women are
biologically different, yet socially equal. Modern medicine can use
this knowledge to alter its practice accordingly in order to promote
the healthiest population possible. There are numerous ways researchers can work towards this goal.
b.

Clinical Trials

i. Varied Biological Responses
One of the key ways to advocate this issue is through changes
in gender treatment of clinical trials. It has been well established that
biological reactions to medical treatments vary depending on the
subgroup of humans being tested.136 A major concern in clinical trials is what researchers call a “directional difference.”137 Directional
differences occur in research outcomes when one trial group benefits
from the treatment, while the other is harmed by the treatment.138
Jesse Berlin and Susan Ellenberg founnd there is no question
that men and women respond differently to treatments and that the
differences in response have hardly been studied and are relatively
unknown.139 Berlin and Ellenberg attribute this lack of data primarily
to the difference in genetics between men and women; “the broader
issue really centers on the biological factors, possibly defined by
genes or gene expression, that may directly or indirectly modify the
effect of specific treatments on specific individuals.”140
ii. Mental Health and Substance Abuse Trials
Mental Health is a rapidly growing concern in the modern
world of medicine, and substance abuse is a growing trend among

136. Jesse A. Berlin & Susan S. Ellenberg, Inclusion of Women in Clinical Trials, 7 BMC
MED. 1, 2 (2009).
137. Berlin & Ellenberg, supra note 136.
138. Id. Berlin and Ellenberg provide an example of a recent medication trial for a heart
failure drug. The medication was successful and effective on black test subjects and
ineffective on white test subjects. If men of different races and the (assumed) same
biological make-up can react differently to a drug, then women can most definitely react differently to drugs than men. Id.
139. Id. at 3.
140. Berlin and Ellenberg anticipate a rise in genetic profiling that could possibly lead to
major discoveries in personalized medicine. Id.
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women.141 Shelly Greenfield found that women trying to enter substance abuse treatment face many barriers.142 They also found evidence that women preferred participating in women-only, as opposed
to mixed-gender, treatment programs.143 Women tended to perceive
women-only treatment programs as safer and more comfortable environments where they can focus on rehabilitation.144 Greenfield attributes this perception to the fact that women and men have differed
risk factors in substance abuse, including but not limited to medical
consequences, reasons for relapse, and co-occurring mental disorders.145
Upon thorough investigation, Greenfield found there are no
empirical studies on women-only treatment groups for substance
abuse.146 “There is [no empirical research] of a manual-based recovery group for women that is not specific for type of substance abuse,
co-occurring psychiatric disorders, or stages of the lifecycle.”147 Nor
were there any studies on generic recovery groups for women.148
Greenfield found this to be disconcerting because the majority of
substance abuse treatment is conducted in a group setting, so they
conducted a comparative treatment between women-only substance
abuse treatment groups and mixed-gender treatment groups to provide empirical data on women in a clinical group setting.149
Greenfield predicted that participants in the all-women test
group would have higher rates of post-treatment satisfaction than the

141. Shelly F. Greenfield et al., The Women’s Recovery Group Study: A Stage I Trial of
Women-Focused Group Therapy for Substance Use Disorders Versus Mixed-Gender
Group Drug Counseling, 9 DRUG & ALCOHOL DEPENDENCE 39 (2007).
142. Id.
143. Id.
144. Id.
145. Id.
146. Greenfield et al., supra note 141. They found the studies researching women-only
groups were largely based on parenting or pregnancy with substance abuse issues. Id.
147. Id. The Greenfield study, conduced in the mid-2000s found that there had never been
any evidence collected regarding women in a substance abuse group therapy setting in
general. Most often, the groups related to pregnancy and parenting for women who
were substance abusers. In fact, they found there had been no studies conducted comparing women-only substance abuse groups to mixed-gender groups. Id.
148. Id.
149. Id.
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participants in the mixed-gender group.150 The research provided evidence that participants in the all-women group reported significantly
higher levels of satisfaction after treatment, supporting the hypothesis.151 The study suggests that the participants of the all-women
group were more satisfied due to enhanced satisfaction of the session
content, as well as their overall experiences in the group process in an
all-woman group.152 This could provide evidence that women may be
more comfortable in clinical treatments without the inclusion of men,
particularly in studies treating mental health diseases.
iii. Menopause and Hormone Therapy
Menopause, though a natural biological process, is not generally an event women eagerly anticipate over the course of their lives.
Around the 1900s, women were beginning to be offered pharmaceutical options to suppress the symptoms of menopause, such as hot
flashes and mood swings.153 These original forms of medications included women ingesting extracts of other animals’ ovaries.154 Various other hormone therapies were attempted throughout the 1960s,
when the anti-menopause culture made a sociological shift.155
Starting in the 1960s, pharmaceutical hormone therapy became
a mass produced answer to the prevention of menopause itself as opposed to suppression of the symptoms.156 Famous gynecologist Dr.
Robert Wilson published the 1966 novel Feminine Forever in which
he predicted that the use of pharmaceutical hormone replacement
therapy could curb the effects of aging in women.157 Dr. Wilson believed that “[t]hrough hormone therapy, a woman could simulate the
hormones of reproduction and thereby stay youthful and attractive
150. Greenfield et al., supra note 141 (“The initial hypothesis of this study was that more
favorable outcomes of the [all-women] group than [mixed-gender] group would result
from a synergy between gender-specific content [and] enhanced group processes, including comfort and cohesion.”
151. Id. at 46.
152. Id.
153. Lisa Faigman, The “M Word” Symposium: An Interdisciplinary Adventure, 23
HASTINGS WOMEN’S L.J. 3, 15 (2012).
154. Id.
155. Id.
156. Jay Schulkin, Hormone Therapy, Dilemmas, Medical Decisions, 36 J.L. MED. &
ETHICS 73, 74 (2008).
157. Id.
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throughout the lifespan. All the right words were in place: youth,
vigor, and sex.”158 Dr. Wilson understood the use of estrogen in
hormone therapy was a way to stay youthful.159 He felt strongly that
physical signs of aging, such as wrinkles, should be avoided.160
Dr. Wilson’s progressive answers to the crisis of aging opened
the floodgates to the business of ending the aging process for women.161 By the early 1970s, hormone therapy had become a popular
treatment among women throughout Western Europe and the United
States.162 In the 1990s, NIH researchers completed a study on women
who used hormone therapy in the 1970s—when it was first administered to women with relatively little clinical trial research.163 Researchers noticed a correlation between hormone use and the development of breast cancer; concluding that the risk of breast cancer inincreases with the frequency of hormone therapy.164 Around the
same time, Great Britain also produced a study that followed 828,923
post-menopausal women and found the same correlation as NIH.165
By 2002, NIH researchers found that the risks associated with
women’s hormone therapy far exceeded the benefits.166 In 2004, after
about forty years of administering a risky form of hormone therapy,
researchers attempted to develop a safer form of hormone therapy for
women.167 This attempt to find safer alternatives has been successful
in modern medicine; however, researchers are continuing to find numerous correlations between use of hormone therapy and increased
risk of cancer.168
It is concerning that this pharmaceutical revolution was developed about fifty years ago based on an opinion by a male gynecol158.
159.
160.
161.

162.
163.
164.
165.
166.
167.
168.

Id.
Id.
Id.
Schulkin, supra note 156. “In other words, women were sold the prospect of staying
young forever. For the pharmaceutical companies this was a homerun, or at least potential homerun, since advertising from pharmaceutical companies significantly contributed to hormone therapy use.” Id.
Id. at 74-75.
Id. at 77.
Id.
Id.
Cynthia A. Stuenkel, Hormone Therapy for Postmenopausal Women: A Brief History
of Time, 23 HASTINGS WOMEN’S L.J. 45, 47 (2012).
Id. at 57.
Id. at 61.
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ogist trying to prevent the physical changes of menopause because
the changes were deemed unbecoming.169 Aside from that, women
were being treated with hormone therapy without clinical research
regarding the risks and negative effects hormone therapy could cause.
Women’s health initiatives are actively working to prevent administration of medical treatments that are not tested. There are still
many who critique the mission of women’s health initiatives.
c. Criticisms of Women’s Health Initiatives and the Neglect
of Men
According to Megan Veith, this shift to women’s health concerns in the recent past has left developments in male health neglected.170 Veith concludes that men are instead the most discriminated
against.171 She finds men to be far more burdened with illnesses than
women throughout their lifespan, and this is reflected by their shorter
projected lifespan.172 Veith argues that men are in much greater need
of medical attention than women and that men’s health should really
be the focus in modern medical treatment.173
She offers intensive research to support her conclusion that
men are at a much higher risk of chronic disease and injury.174 Veith
notes men lead much riskier lifestyles; they are more likely to engage
in activities such as binge drinking alcohol, driving without a seatbelt, and playing riskier sports.175 Veith argues that men’s sexual activity is much riskier than women’s, yet she makes no counterargument in regards to instances against women in powerless situations,
such as genital mutilation and domestic violence.176 She emphasizes

169.
170.
171.
172.
173.
174.
175.

Schulkin, supra note 156.
Veith, supra note 80, at 352.
Id.
Id. at 354.
Id. at 353.
Id. at 352.
Schulkin, supra note 156, at 353. “Regarding risky behaviors and health, men also
‘abuse alcohol and other drugs at least twice as often [as women] and commit 86% of
all violent crimes.’ Moreover, males participate in riskier sports and recreational activities than females. In terms of mental health such as depression, men may be underdiagnosed and under-treated. Finally, in the most recent US military operations. many
more men died than did women.” Id.
176. Id.
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that men reported remarkably higher rates of syphilis and HIV.177 Finally Veith found, “men are also more likely than women to develop
some forms of cancer including lung, colorectal, throat, stomach,
pancreas, bladder, non-Hodgkin’s lymphoma and leukemia.”178
It is entirely possible that resources have not been spread equally
among gender-based medical treatments. However, Veith fails to
take a more holistic look at society. There is little in response to the
psychological and sociological treatment of women throughout the
world. She eloquently states, “a more progressive and beneficial way
to look at gender and medicine is not to look to whether men or
women are more entitled to healthcare, but to look at how medicine
can be used to benefit both genders.”179
The purpose of this comment is not to present evidence to steer
healthcare away from developing men’s health, but to ensure genders
are recognized for their biological differences and thus seek the most
optimum healthcare for all people throughout the world. It is important to look at both genders as different biological beings in order
to shape medical treatments to improve the lives of everyone. This
comment is meant to provide a holistic representation of women in
society, how they are faced with different challenges and barriers
than men, and how this affects women’s healthcare.
IV. The Future for Women Around the World
a. Women and Health Initiative and a Global Perspective
It is imperative that all people around the world, no matter
their biological sex, are provided with the best healthcare possible.
The Agenda is working to accomplish well-rounded healthcare for all
women.180 Through the primary collection of research on nonreproductive chronic diseases in women and finding ways to include
women in clinical trials, global public health will improve greatly.

177. Id.
178. Id. at 354. She does attribute some of these numbers to men being less likely to engage
in any sort of preventative health treatments of screenings than women. She mentions
that when men have breast cancer, about 1% of the cases, they are much more likely
die from the cancer than women. Id.
179. Schulkin, supra note 156, at 352.
180. Fleck, supra note 1, at 629.
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From the structuralism perspective, women have been treated
as lesser citizens in the realm of medical research and clinical trials.
Since the Thalidomide tragedy, the consideration to exclude women
who are pregnant or are trying to get pregnant from clinical trials is
understandable. Clinical trials involve the risk of at least one human,
and thus it is justifiable to exclude a person carrying an even more
vulnerable person. The key problem, however, is that these medications, once approved in trials using men, are then administered to
women. This appears to be an even riskier way to test female responses to drugs.
Though reproductive protection is vital to the survival of mankind, it is not the only health risk for which women need protection.
In fact, HIV/AIDS is currently the leading cause of death among
women around the world between the ages of fifteen and forty-nine,
followed by maternal complications.181 The third is self-harm and
mental health disorders.182 Melinda Gates notes that women’s health
is facing a fast-growing epidemic of chronic diseases among women,
such as cancer, diabetes, and cardiovascular diseases, and that noncommunicable diseases are rapidly rising in rank.183
Gates states, “[t]hese findings raise important questions for
government leaders, health experts, and parents. How are underlying
social detriments of women’s health affecting life options of girls and
women? Are government policies sufficiently focused on these critical stages in the life course to ensure that girls grow into healthy,
productive women?”184 These important questions are what the
Agenda seeks to answer.
Throughout the world, options remain limited for women’s
health. This is attributed to biological, psychological, and sociological factors often barring equal access to women’s healthcare. The
Agenda seeks to understand how women fit into society, not simply
as reproductive beings.185 Richard Horton and Audrey Ceschia are
hopeful that modern globalization is shrinking the gaps of inequality
181. Melinda Gates, Valuing the Health and Contribution of Women is Central to Global
Development, 386 THE LANCET e11, e12 (2015).
182. Id.
183. Id.
184. Id.
185. Richard Horton & Audrey Ceschia, Making Women Count, 386 THE LANCET 1112,
1113 (2015).

120

Not Really a Battle of the Sexes

Vol. IV, No. II

between countries.186 However, they are fearful that globalization has
aggravated inequalities within countries.187 With increased communication and travel, all countries have been pulled into the limelight
and are being watched by their fellow countries.188 Globalization has
produced social tensions that are negatively affecting the stability of
societies.189 Treatment outside of direct biological needs can raise the
esteem of women, thus preventing mental health issues and improving overall physical health.190
At the most primitive, without healthy women, there is an unsustainable society. If women’s health is neglected around the world,
then as a society, about half of the world’s population is being neglected.191 In both Western society and developing countries, lack of
healthcare feeds into endless cycles of poverty and violence.192
b. The Future for Gender and Medicine
There is hope for the future of gender and medicine. “Western
society has seen women gain the right to vote, receive higher education, and continue on to careers in similar positions of authority as
their male counterparts. Thus…why would something so fundamental and essential as women’s health continue to be constrained by
male-oriented and male-dominated clinical trials?”193
There may be critics to the shift of focusing on women’s
health, and though some arguments have merit, it is not a battle to
eliminate male healthcare research. The key to a well-balanced
healthcare system is to treat every person in the best and safest way
possible. Numerous trials have provided evidence that recognizes the
need for distinguishing effects based on gender.
Chronic and non-communicable diseases are on the rise among
the female population. In a study produced by Niewada in Warsaw,

186.
187.
188.
189.
190.

Id.
Id.
Id.
Id.
See generally Jim Yong Kim & Timothy Evans, Promoting Women’s Health for Sustainable Development, 386 THE LANCET e9 (2015).
191. Id. at e10.
192. Id.
193. Breanna Sergent, To Include or to Exclude? The Policy Question Plaguing Women’s
Role in Clinical Trials, 34 J. LEG. MED. 235 (2013).
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Poland, the researchers studied over 17,000 stroke patients.194 Their
conclusion stressed the differences in reactions between the male and
female patients and that “further research to explore the underlying
biological mechanism is justified [to] improve [health] outcomes of
female patients.”195 Around the world, medical researchers are finding differences between genders, which will hopefully be implemented in future medical treatments and clinical trials. The question of
including pregnant women in clinical trials continues to be addressed
by researchers and will likely be an ethical dilemma addressed in the
foreseeable future.196
There have been numerous laws enacted by governments to
protect vulnerable populations such as prisoners, children, and pregnant women.197 According to Barbara Noah, the research culture is
very much against the inclusion of pregnant women.198 However,
there have been great strides in clinical trials towards women and this
mentality may change. Some have suggested that when there is a potential risk to the fetus in a clinical trial, consent from both the mother and father should be required to create a fail-safe system for the research liability.199 Over the past decade, numerous arguments have
been presented in favor of including women who are pregnant or can
become pregnant in trials.200 To develop further understanding of the
overall health of women, the inclusion of this population, while risky,
could continue to close the discrimination gap being fought by the
Agenda.
The future for gender recognition is seemingly positive. There
are still health concerns for women, but history has shown quite a
shift in the past fifty years in regard to the treatment of women in at
least Western society. For developing countries, this may unfortunately take quite a bit longer. The Agenda will continue to close this
194. Maciej Niewada et al., Influence of Gender on Baseline Features and Clinical Outcomes among 17,370 Patients with Confirmed Ischaemic Stroke in the International
Stroke Trial, 24 NEUROEPIDEMIOLOGY 123 (2004).
195. Id.
196. Barbara A. Noah, The Future of Health Law: Exemplary Insight Into Trending Topics:
The Inclusion of Pregnant Women in Clinical Research, 7 ST. LOUIS U. J. HEALTH L. &
POL’Y 353, 372 (2014).
197. Id.
198. Id.
199. Id. at 376.
200. Id.
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gap in treatment. It is an essential human right to all people to benefit from global health developments.
V. Conclusion
The Agenda will hopefully improve the global health of women. Their mission is to better understand the biology of women and
how it differs from the biology of men. There is a great deal of evidence suggesting that there are marked differences between the sexes
and they produce differed reactions to treatment. As the new health
agenda continues advocating against the discrimination of women,
global health will improve.
History has shown that women have not had their needs met to
the extent that men have in the realm of healthcare around the world.
In the twenty-first century, it is time to change the conversation. The
improvement of global health is not only a moral duty in order to
grant this essential human right, but a way to work towards ending
worldwide poverty and crime. For survival, health is a fundamental
need—not only for women, but for mankind in general. All people
deserve to have that need met. The New Women’s Health Agenda
will have a positive impact on women and the world.
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